Form 8-K - Current report:
SEC Accession No. 0000950170-25-004566
Filing Date
2025-01-13
Accepted
2025-01-13 07:35:16
Documents
36
Period of Report
2025-01-13
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K lxeo-20250113.htm   iXBRL 8-K 46999
2 EX-99.1 lxeo-ex99_1.htm EX-99.1 31016
3 GRAPHIC lxeo-ex99_1s1.jpg GRAPHIC 219186
4 GRAPHIC lxeo-ex99_1s2.jpg GRAPHIC 553780
5 GRAPHIC lxeo-ex99_1s3.jpg GRAPHIC 393715
6 GRAPHIC lxeo-ex99_1s4.jpg GRAPHIC 471018
7 GRAPHIC lxeo-ex99_1s5.jpg GRAPHIC 336031
8 GRAPHIC lxeo-ex99_1s6.jpg GRAPHIC 416486
9 GRAPHIC lxeo-ex99_1s7.jpg GRAPHIC 186575
10 GRAPHIC lxeo-ex99_1s8.jpg GRAPHIC 418162
11 GRAPHIC lxeo-ex99_1s9.jpg GRAPHIC 377079
12 GRAPHIC lxeo-ex99_1s10.jpg GRAPHIC 445296
13 GRAPHIC lxeo-ex99_1s11.jpg GRAPHIC 440139
14 GRAPHIC lxeo-ex99_1s12.jpg GRAPHIC 434273
15 GRAPHIC lxeo-ex99_1s13.jpg GRAPHIC 464530
16 GRAPHIC lxeo-ex99_1s14.jpg GRAPHIC 385782
17 GRAPHIC lxeo-ex99_1s15.jpg GRAPHIC 386877
18 GRAPHIC lxeo-ex99_1s16.jpg GRAPHIC 404690
19 GRAPHIC lxeo-ex99_1s17.jpg GRAPHIC 181469
20 GRAPHIC lxeo-ex99_1s18.jpg GRAPHIC 488250
21 GRAPHIC lxeo-ex99_1s19.jpg GRAPHIC 372914
22 GRAPHIC lxeo-ex99_1s20.jpg GRAPHIC 413809
23 GRAPHIC lxeo-ex99_1s21.jpg GRAPHIC 377959
24 GRAPHIC lxeo-ex99_1s22.jpg GRAPHIC 413686
25 GRAPHIC lxeo-ex99_1s23.jpg GRAPHIC 385533
26 GRAPHIC lxeo-ex99_1s24.jpg GRAPHIC 184571
  Complete submission text file 0000950170-25-004566.txt   12811959

Data Files

Seq Description Document Type Size
27 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lxeo-20250113.xsd EX-101.SCH 25989
38 EXTRACTED XBRL INSTANCE DOCUMENT lxeo-20250113_htm.xml XML 4931
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41855 | Film No.: 25524819
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)